We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+27.1%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$168M
AUM Growth
+$5.88M
Cap. Flow
-$18.5M
Cap. Flow %
-10.98%
Top 10 Hldgs %
44.13%
Holding
98
New
36
Increased
11
Reduced
15
Closed
33
Avg Time Held Equity + Options
0.1 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 51.15%
2 Healthcare 48.85%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$18.1B
$17.5M 10.36%
+150,000
New +$12.2M
2014 Q1
0 quarters
MRK icon
2
CALL
Merck
MRK
$330B
$14.2M 8.43%
+262,000
New +$13.6M
2014 Q1
0 quarters
TEVA icon
3
CALL
Teva Pharmaceutical Industries
TEVA
$45.8B
$7.93M 4.71%
150,000
+50,000
+50% +$2.31M
2013 Q4
1 quarter
GILD icon
4
CALL
Gilead Sciences
GILD
$206B
$7.09M 4.21%
100,000
– –
2013 Q4
1 quarter
BMY icon
5
CALL
Bristol-Myers Squibb
BMY
$120B
$5.2M 3.08%
+100,000
New +$5.32M
2014 Q1
0 quarters
VTRS icon
6
CALL
Viatris
VTRS
$22.5B
$4.88M 2.9%
+100,000
New +$4.86M
2014 Q1
0 quarters
AEGR
7
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$4.62M 2.74%
+100,000
New +$5.86M
2014 Q1
0 quarters
VRTX icon
8
CALL
Vertex Pharmaceuticals
VRTX
$131B
$4.6M 2.73%
65,000
– –
2013 Q4
1 quarter
PRTA icon
9
Prothena
PRTA
$422M
$4.21M 2.5%
110,000
-20,000
-15% -$645K
2013 Q4
1 quarter
BMY icon
10
Bristol-Myers Squibb
BMY
$120B
$4.16M 2.47%
80,000
-20,000
-20% -$1.06M
2013 Q4
1 quarter
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$4.02M 2.39%
300,000
+180,000
+150% +$1.93M
2013 Q4
1 quarter
ARAY icon
12
Accuray
ARAY
$6.24M
$3.84M 2.28%
10,000
-1,250
-11% -$473K
2013 Q4
1 quarter
INSM icon
13
CALL
Insmed
INSM
$31B
$3.81M 2.26%
+200,000
New +$3.8M
2014 Q1
0 quarters
AMAG
14
DELISTED
AMAG Pharmaceuticals
AMAG
$3.72M 2.21%
+192,057
New +$4.08M
2014 Q1
0 quarters
CHTP
15
DELISTED
Chelsea Therapeutics International
CHTP
$3.31M 1.97%
600,000
+500,000
+500% +$2.51M
2013 Q4
1 quarter
UNIS
16
DELISTED
Unilife
UNIS
$3.26M 1.93%
80,000
+45,000
+129% +$2.03M
2013 Q4
1 quarter
CYH icon
17
Community Health Systems
CYH
$228M
$3.13M 1.86%
96,800
+12,100
+14% +$400K
2013 Q4
1 quarter
ARWR icon
18
Arrowhead Research
ARWR
$5.85B
$3.04M 1.8%
185,000
-90,000
-33% -$1.58M
2013 Q4
1 quarter
TRNX
19
DELISTED
Tornier
TRNX
$2.76M 1.64%
130,000
+30,000
+30% +$582K
2013 Q4
1 quarter
ICPT
20
DELISTED
Intercept Pharmaceuticals
ICPT
$2.64M 1.57%
+8,000
New +$2.7M
2014 Q1
0 quarters
INSM icon
21
Insmed
INSM
$31B
$2.57M 1.53%
135,000
-65,000
-33% -$1.24M
2013 Q4
1 quarter
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.22B
$2.54M 1.51%
11,500
+7,000
+156% +$1.78M
2013 Q4
1 quarter
MMSI icon
23
Merit Medical Systems
MMSI
$5.05B
$2.5M 1.49%
+175,000
New +$2.6M
2014 Q1
0 quarters
OCRX
24
DELISTED
Ocera Therapeutics
OCRX
$2.48M 1.47%
235,000
+160,000
+213% +$2.29M
2013 Q4
1 quarter
FURX
25
DELISTED
Furiex Pharmaceuticals
FURX
$2.39M 1.42%
+27,500
New +$2.12M
2014 Q1
0 quarters

Similar funds

Ghost Tree Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Ghost Tree Capital held 98 positions worth $168M, up 3.6% from $163M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital withdrew a net $18.5M in Q1 2014, closing 33 positions and reducing 15 holdings. Its most notable exit was Gilead Sciences, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, up from 44% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Ghost Tree Capital opened a new position in AMAG Pharmaceuticals worth $3.72M.

  • Ghost Tree Capital's largest Q1 2014 buy was AMAG Pharmaceuticals: 192,057 shares worth $3.72M.
  • Ghost Tree Capital added most to Chelsea Therapeutics International in Q1 2014, an estimated $2.51M increase.
  • Ghost Tree Capital's biggest Q1 2014 reduction was Spectranetics, cutting an estimated $3.42M.
  • Ghost Tree Capital fully exited Gilead Sciences in Q1 2014, selling an estimated $10.6M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $168M portfolio in Q1 2014.
  • Ghost Tree Capital opened 36 new positions and closed 33 in Q1 2014.
  • Ghost Tree Capital's portfolio value rose 3.6% quarter-over-quarter to $168M.

Based on Ghost Tree Capital's 13F filing for Q1 2014, filed 15 May 2014.